Copyright 2024
| PMID | Allele | Disease | Population | Drug Names | SNP | Class | Sentence |
|---|---|---|---|---|---|---|---|
| 12942703 | HLA-DR (HLA-DR) | adult onset stills disease | NA | NA | NA | unclassified | |
| association between hla-dr b1 and clinical features of adult onset still's disease in korea. | |||||||
| 12942703 | HLA-DR (HLA-DR) | adult onset stills disease | NA | NA | NA | unclassified | |
| to determine whether hla-dr alleles are associated with the development and clinical features of adult onset still's disease (aosd) in korea. | |||||||
| 12959223 | HLA-G (HLA-G) | placental abruption | NA | NA | NA | negative | |
| placental abruption is associated with decreased maternal plasma levels of soluble hla-g. during pregnancy the fetus represents a semi-allograft. | |||||||
| 17434600 | HLA-CLASS II (HLA-CLASS II) | placental abruption | Caucasian | NA | NA | unclassified | |
| we have found that recurrent placental abruption is exclusively almost preceded by the birth of a boy and the majority of patients have hla-class ii known to restrict cd4 t-cell reactions against hy-antigens. | |||||||
| 15241071 | HLA-B*46 | severe acute respiratory syndrome | NA | NA | NA | unclassified | |
| insights into the pathogenesis of severe acute respiratory syndrome have been made: one study suggests that human leukocyte antigen hla-b*4601 is a possible risk factor for more severe disease, while another identifies angiotensin-converting enzyme 2 as a cellular receptor for severe acute respiratory syndrome-associated coronavirus. | |||||||
| 15451471 | HLA-A*02 | severe acute respiratory syndrome | NA | NA | NA | only_studied | |
| to assess specific cytotoxic t lymphocytes (ctls) against severe acute respiratory syndrome (sars)-coronavirus, a modified dimerx flow cytometry assay was performed with peripheral blood mononuclear cell (pbmc) from hla-a2+ sars-recovered donors at different time points post disease. | |||||||
| 16278955 | HLA-A*02 | severe acute respiratory syndrome | NA | NA | NA | unclassified | |
| two hla-a2 hot-spots in severe acute respiratory syndrome coronavirus (sars-cov) membrane protein were predicted by using multipred. | |||||||
| 16630549 | HLA-A*02 | severe acute respiratory syndrome | NA | NA | NA | unclassified | |
| hla-a*0201 t-cell epitopes in severe acute respiratory syndrome (sars) coronavirus nucleocapsid and spike proteins. | |||||||
| 16630549 | HLA-A*02 | severe acute respiratory syndrome | NA | NA | NA | unclassified | |
| the immunogenicity of hla-a*0201-restricted cytotoxic t lymphocyte (ctl) peptide in severe acute respiratory syndrome coronavirus (sars-cov) nuclear capsid (n) and spike (s) proteins was determined by testing the proteins' ability to elicit a specific cellular immune response after immunization of hla-a2.1 transgenic mice and in vitro vaccination of hla-a2.1 positive human peripheral blood mononuclearcytes (pbmcs). | |||||||
| 16630549 | HLA-A*02 | severe acute respiratory syndrome | NA | NA | NA | unclassified | |
| the immunogenicity of hla-a*0201-restricted cytotoxic t lymphocyte (ctl) peptide in severe acute respiratory syndrome coronavirus (sars-cov) nuclear capsid (n) and spike (s) proteins was determined by testing the proteins' ability to elicit a specific cellular immune response after immunization of hla-a2.1 transgenic mice and in vitro vaccination of hla-a2.1 positive human peripheral blood mononuclearcytes (pbmcs). | |||||||
Copyright 2024